Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AN8025 is a multifunctional antibody fusion protein
AN8025 · 1 trial · 1 indication
Incidence, nature and severity of adverse events (AEs) according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Nature and frequency of dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| AN2025 Treatment | EXPERIMENTAL | AN8025 is a tri-functional antibody that is a reconstituted liquid intravenously administered over the period of 60 mins. |
| Name | Type | Description |
|---|---|---|
| AN8025 is a multifunctional antibody fusion protein | DRUG | AN8025 is being developed for the treatment of advanced or metastatic solid tumors, which may include PD(L)-1 refractory advanced solid tumors |
Inclusion Criteria: 1. Aged ≥18 years old. 2. Able to provide informed consent obtained before any study-related activities and according to local guidelines. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. 4. Have an estimated life expectancy ≥ 12 weeks, in the judgment ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AN8025 is being studied for the treatment of advanced solid tumors. It is an investigational therapy in Phase 1 clinical development and has not been approved for any indication. The ongoing trial enrolls adults with advanced solid tumors in Australia.
AN8025 targets PD-L1, a protein that tumors use to suppress immune responses. By binding PD-L1, AN8025 is designed to interfere with this immune evasion pathway. It is described as a multifunctional antibody fusion protein, combining antibody targeting with additional functional domains.
AN8025 is being developed by Adlai Nortye Ltd., whose American Depositary Shares trade under the ticker ANL. The company is advancing the candidate through early clinical testing in oncology.
AN8025 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The Phase 1 program is evaluating the therapy in patients with advanced solid tumors.
AN8025 is being evaluated in a single Phase 1 trial, NCT07639047, titled An Initial Evaluation of AN8025 in Solid Tumors. The study is currently recruiting approximately 91 participants aged 18 years and older in Australia. It is an uncontrolled, open-label trial without randomization or blinding.
Yes, AN8025 is described as a multifunctional antibody fusion protein. This designation reflects its molecular design, which combines antibody targeting with fusion protein components. It is distinct from conventional small molecule or simple antibody therapies.